Fluid therapy with hydroxyethyl starch for massive blood loss during surgery

Journal of Anesthesia

Volumn 24, Issue 3, 2010, Pages 418-425

  Suzuki, Toshinari ^a   Miyao, Hideki ^a   Terui, Katsuo ^a   Koyama, Kaoru ^a   Shiibashi, Michio ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adverse effects; Coagulation disorders; HES70 0.55 4; Massive bleeding; Renal complications

Indexed keywords

CREATININE; HETASTARCH;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; FLUID THERAPY; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; KIDNEY INJURY; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PATIENT SELECTION; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROTHROMBIN TIME; SURVIVAL RATE; URINE VOLUME;

ADULT; AGED; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD LOSS, SURGICAL; CREATININE; DATABASES, FACTUAL; FEMALE; FLUID THERAPY; HEMOSTASIS; HETASTARCH; HUMANS; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE, ACUTE; LOGISTIC MODELS; MALE; MIDDLE AGED; PLASMA SUBSTITUTES; POSTOPERATIVE HEMORRHAGE; RENAL CIRCULATION; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77954534604     PISSN: 09138668     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00540-010-0914-5     Document Type: Article

References (20)

1. WL Adcock A MacGregor JR Davies M Hattarki DA Anderson NH Goss 1998 Chromatographic removal and heat inactivation of hepatitis A virus during manufacture of human albumin Biotechnol Appl Biochem 28 85 94 1:CAS:528:DyaK1cXlsVWqsrk%3D 9693093 (Pubitemid 28369910)
2. J Blümel I Schmidt H Willkommen J Löwer 2002 Inactivation of parvovirus B19 during pasteurization of human serum albumin Transfusion 42 1011 1018 10.1046/j.1537-2995.2002.00158.x 12385412
3. Thyer J, Unal A, Thomas P, Eaton B, Bhashyam R, Ortenburg J, Uren E, Middleton D, Selleck P, Maher D. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins. Vox Sang. 2006;91:292-300.
4. I Roberts 1998 (Cochrane Injuries Group Albumin Reviewers) Human albumin administration in critically ill patients: systematic review of randomized controlled trials Br Med J 317 235 239
5. The SAFE Study Investigators 2004 A comparison of albumin and saline for fluid resuscitation in the intensive care unit N Engl J Med 350 2247 2256 10.1056/NEJMoa040232 (Pubitemid 38669207)
6. Johnson ML, Gordon HS, Petersen NJ, Wray NP, Shroyer AL, Grover FL, Geraci JM. Effect of definition of mortality on hospital profiles. Med Care. 2002;40:7-16.
7. Molitoris BA, Levin A, Warnock DG, Joannidis M, Mehta RL, Kellum JA, Ronco C, Shah SV. Improving outcomes of acute kidney injury: report of an Initiative. Nat Clin Pract Nephrol. 2007;3:439-42. (Pubitemid 47123586)
8. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:31.
9. ®, a physiologically balanced plasma expander for large volume use in major surgery: a randomized Phase III clinical trial. Anesth Analg. 1999;88:992-8.
10. ®) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth. 2000;47:1207-15.
11. M Westphal MFM Jame S Kozek-Langenecker R Stocker B Guidet HV Aken 2009 Hydoroxyethyl starches Anesthesiology 111 187 202 10.1097/ALN.0b013e3181a7ec82 1:CAS:528:DC%2BD1MXnsFyjtr0%3D 19512862
12. H Yamazaki 1975 Effects of low-molecular weight HES on kidney-comparison with low-molecular weight dextran (in Japanese with English abstract) Jpn J Anesthesiol 24 26 43
13. JM Mishler 1984 Synthetic plasma volume expanders-their pharmacology, safety and clinical efficacy Clin Haematol 13 75 92 1:CAS:528:DyaL2cXktFKmu7w%3D 6202449
14. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125-39.
15. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effects of hydroxyethyl starch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet. 2001;357:911-6.
16. J Boldt C Brosch K Rohm A Lehmann A Mengistu S Suttner 2008 Is albumin administration in hypoalbuminemic elderly cardiac surgery patients of benefit with regard to inflammation, endothelial activation, and long-term kidney function? Anesth Analg 107 1496 1503 10.1213/ane.0b013e31818370b2 1:CAS:528:DC%2BD1cXht1KnsrzN 18931204
17. J Treib A Haass G Pindur 1997 Coagulation disorder caused by hydroxyethyl starch Thromb Haemost 78 974 983 1:CAS:528:DyaK2sXmtVejsro%3D 9308738
18. M Yamakage J Sato A Namiki 2005 Further potential of hydroxyethyl starch-based plasma substitute (in Japanese with English abstract) J Clin Anesth (Japan) 29 61 73
19. H Yuasa Y Koga 1998 Effects of hydroxyethyl starch on hemostasis system (in Japanese with English abstract) J Clin Anesth (Japan) 22 204 208
20. M Dalrymple-Hay R Aitchison P Collins M Sekhar B Colvin 1992 Hydroxyethylstarch induced acquired von Willebrand's disease Cin Lab Haematol 14 209 211 1:STN:280:DyaK3s%2FotlShtQ%3D%3D